PRESS RELEASE published on 04/22/2026 at 23:30, 6 months 9 days ago Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Sanofi and Regeneron's Dupixent approved as first biologic medicine for young children with uncontrolled chronic spontaneous urticaria, expanding previous approval for adults and adolescents Sanofi Dupixent CSU Regeneron Biologic Medicine
BRIEF published on 04/18/2026 at 12:05, 6 months 13 days ago Sanofi's Vaccine Shows Superior Tolerability in Recent Study COVID-19 Sanofi Nuvaxovid Vaccine Study Tolerability
BRIEF published on 04/18/2026 at 12:05, 6 months 13 days ago Sanofi's Nuvaxovid demonstrates better tolerability compared to mNEXSPIKE Sanofi Tolérance Nuvaxovid ESCMID COVID-19 Vaccination
PRESS RELEASE published on 04/18/2026 at 12:00, 6 months 13 days ago Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study Sanofi's Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in a head-to-head study presented at ESCMID Global Congress. Results indicate lower side effects and improved patient experience COVID-19 Sanofi Vaccine Nuvaxovid Tolerability
BRIEF published on 04/13/2026 at 07:05, 6 months 19 days ago Sanofi and Regeneron’s Dupixent Gains EU Approval for Treating Young Children with CSU Sanofi Dupixent EU Approval Regeneron Chronic Spontaneous Urticaria
BRIEF published on 04/13/2026 at 07:05, 6 months 19 days ago Dupixent from Sanofi and Regeneron approved for young children in the EU Children Dupixent Chronic Urticaria Sanofi Regeneron EU Supply
PRESS RELEASE published on 04/13/2026 at 07:00, 6 months 19 days ago Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Sanofi and Regeneron's Dupixent approved in the EU for young children with chronic spontaneous urticaria, expanding treatment options to address type 2 inflammation EU Sanofi Dupixent Regeneron Chronic Spontaneous Urticaria
BRIEF published on 04/07/2026 at 07:05, 6 months 25 days ago Sanofi's Lunsekimig Shows Promise in Asthma and CRSwNP Studies Sanofi CRSwNP Asthma Lunsekimig Phase 2 Studies
PRESS RELEASE published on 04/07/2026 at 07:00, 6 months 25 days ago Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP Sanofi's lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP, showing promising results for managing respiratory diseases Respiratory Diseases Sanofi Asthma Lunsekimig Phase 2 Studies
BRIEF published on 03/28/2026 at 16:05, 7 months 4 days ago Sanofi's Amlitelimab Shows Promising Results in Phase 3 Atopic Dermatitis Studies Clinical Development Sanofi Atopic Dermatitis Phase 3 Studies Amlitelimab
Published on 10/30/2026 at 23:35, 2 days 10 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 10 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 14 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 18 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 09:30, 27 minutes ago Europe's first bond for New Space investing is open for subscription from today: European Space Bond, 8% p.a. fixed interest.
Published on 11/02/2026 at 09:20, 36 minutes ago Original-Research: SFC Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/02/2026 at 09:00, 56 minutes ago Original-Research: Gallmetzer HealthCare SpA (von NuWays AG): BUY
Published on 11/02/2026 at 09:00, 56 minutes ago Original-Research: bet-at-home.com AG (von NuWays AG): BUY
Published on 11/02/2026 at 09:00, 57 minutes ago Mutares has sold SRT Group and its subsidiaries to Quiver
Published on 10/30/2026 at 23:00, 2 days 10 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 15 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 21 hours ago Capital increase through exercise of subscription rights